Stay tuned
Earnings bulletin: Johnson & Johnson's second quarter of 2019
Several Johnson & Johnson drugs are contributing strong growth, b
J&J called 'kingpin' of Oklahoma opioid epidemic. Will a judge agree?
Called a “kingpin” and accused of launching a “multibillion bra
J&J execs have plenty to brag about in pharma. Why downplay Xarelto, Zytiga woes?
Johnson & Johnson's pharma unit is still churning out growth, par
Novartis’ crizanlizumab wins speedy FDA review, putting it closer to blockbuster sickle cell launch
Novartis’ plan to launch over 10 potential blockbuster drugs or new
Who's toughest on drug prices? Watch Trump and his 2020 challengers wrestle for the title
As the 2020 election revs up, candidates are again targeting drug pri
Stay tuned
© 1994 - 2019 B.M. Pharmaceuticals